Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by mstrmndon Oct 16, 2021 3:33pm
178 Views
Post# 34013781

RE:RE:RE:RE:RE:RE:RE:Time to Market for H2S Pipeline

RE:RE:RE:RE:RE:RE:RE:Time to Market for H2S PipelineYes, completely agree.  This was briefly discussed at the AGM as well by Stauffer although at that time awaiting biomarker confirmation. 

150 mg x 90 days will not work due to p450 inhibition.  Loading could work although challenging for OTC marketing.  

150 mg x 14 days works despite p450 inhibition, both safe and effective, hence new strategy.

The answer for chronic use could be as simple as 75 mg x 14 days (25 mg tabs every 8 hours) and then 25 mg daily x 90 days, as you say.  Trial should allow for dose reduction on upon LTE prior to discontinuation.


Rawrasaurus wrote:
Mstrmind, I'll look it up but there is parti cyp 450 inhibition. I mentioned it in ceo but I believe it is the c9 pathway (don't quote me til I find the study). It almost certainly is building up due to his inhibition, but can also almost certainly be corrected by dropping the dose and requiring a longer ramp up time before we see clinical significance. From a clinical use, I could see this requiring a loading dose for a few days to a week before the dose gets dropped back to a low once daily dose to maintain serum levels.


<< Previous
Bullboard Posts
Next >>